IGM Biosciences to cut 73% of workforce
IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...
Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company ...
Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...
Hosted on MSN11h
Stifel Downgrades IGM Biosciences (IGMS)Fintel reports that on January 10, 2025, Stifel downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold ...
IGM Biosciences (IGMS) stock faces sharp selloff as the company abandons two therapeutic candidates, triggering Wall Street ...
Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...
JPMorgan upgraded IGM Biosciences (IGMS) to Neutral from Underweight without a price target The firm says that with the company announcing ...
GlobalData on MSN1d
IMG Biosciences enacts massive lay-offs after Phase I trial failureFollowing the negative Phase I trial outcome for its autoimmune disease treatment, the company is cutting 73% of jobs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback